

**Washington State Pharmacy and Therapeutics Committee
Drug Utilization Review Board
Date: October 21, 2020
Time: 9 a.m. to 4 p.m.
GoTo Webinar**

9 a.m.	Welcome & Introductions Pharmacy & Therapeutics Committee Convenes (Reviews drug classes for the WA PDL)	Ginni Buccola, Committee Chair
9:05 a.m.	Multiple Sclerosis- updated report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Beth Shaw, DERP
10:20 a.m.	Pharmacy & Therapeutics Committee Adjourns Break	Ginni Buccola, Committee Chair
10:40 a.m.	Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Ginni Buccola, Committee Chair
10:40 a.m.	Antihyperlipidemics : Microsomal Triglyceride Transfer Protein (MTP) Inhibitor <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
10:42 a.m.	Antihyperlipidemics : PCSK-9 Inhibitors <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
10:44 a.m.	Antivirals : HIV <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
11:30 a.m.	Antivirals : Influenza Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
11:38 a.m.	Cardiovascular Agents : Sinus Node Inhibitors <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
11:40 a.m.	Endocrine And Metabolic Agents : Pituitary Suppressants <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
11:48 a.m.	Gastrointestinal Agents : Irritable Bowel Syndrome (IBS) Agents / GI Motility <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
11:55 a.m.	Gastrointestinal Agents : Phosphate Binder Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
12 p.m.	LUNCH	All
12:30 p.m.	Genitourinary Agents : Overactive Bladder Agents <ul style="list-style-type: none"> • Stakeholder input* 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> • Motion 	
12:40 p.m.	Hematological Agents : Hereditary Angioedema Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
12:42 p.m.	Miscellaneous Therapeutic Classes : Potassium Removing Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
12:50 p.m.	Multiple Sclerosis Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
1:10 p.m.	Oncology Agents : Lhrh Analogs – Injectable <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
1:18 p.m.	Substance Use Disorder : Agents For Opioid Withdrawal <ul style="list-style-type: none"> • Opioid Antagonists • Opioid Partial Agonists – Subcutaneous • Opioid Partial Agonists – Transmucosal <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
1:35 p.m.	BREAK	All
1:45 p.m.	Archived Apple Health Drug Classes (see addendum) <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
2:40 p.m.	Apple Health Policy- Buprenorphine <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Luke Dearden, HCA
3 p.m.	Apple Health Policy- Sublocade <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Luke Dearden, HCA
3:20 p.m.	Apple Health Policy- PCSK9 <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
3:40 p.m.	Apple Health Policy- IBS/GI Motility <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
4 p.m.	Drug Utilization Review Board Adjourns	Ginni Buccola, Committee Chair

For all Apple Health (Medicaid) questions, please email AppleHealthPharmacyPolicy@hca.wa.gov.

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.